Low-grade Upper Tract Urothelial Cancer Videos

Videos

First-Line Treatment Approaches for Metastatic Urothelial Cancer in the US

05/04/2021

Petros Grivas, MD, PhD, discusses results from a study exploring decision-making processes regarding first-line treatment choices, testing practices and treatment eligibility determinants for patients with metastatic urothelial cancer.

Petros Grivas, MD, PhD,...

05/04/2021

Journal of Clinical Pathways

Videos

Real-World Survival Trends in Muscle-Invasive Bladder Cancer and Urothelial Carcinoma

03/12/2021

Nimira Alimohamed, MD, discusses results from a real-world analysis of outcomes over time in patients with muscle-invasive bladder cancer and patients with metastatic urothelial carcinoma.

Nimira Alimohamed, MD, discusses...

03/12/2021

Journal of Clinical Pathways

Videos

Study Finds No Correlation Between Antibiotic Use and OS in Metastatic Urothelial Carcinoma

02/19/2021

Shilpa Gupta, MD, discusses the effect of antibiotic use within 30 days of initiation of immune checkpoint inhibitors on overall survival among patients with metastatic urothelial carcinoma in real-world practice.

Shilpa Gupta, MD, discusses the...

02/19/2021

Journal of Clinical Pathways

What's Trending?

News Connection

Patients’ Use of Multiple Acute Care Facilities

02/15/2011

Tori Socha

Timely access to patients’ health information is a key component in delivering effective and safe medical treatment.

Timely access to patients’...

02/15/2011

First Report Managed Care

News

TAVR may help recovery of cognitive function

10/19/2016

By David DouglasNEW YORK (Reuters Health) -...

...

10/19/2016

Population Health

News

FDA Approves New Drug to Treat Irritable Bowel Syndrome and Constipation

10/16/2012

On August 30, 2012, the FDA approved Linzess (linaclotide) for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation (IBS-C) in adults. Constipation is one of the most common gastrointestinal...

On August 30, 2012, the FDA...

10/16/2012

Annals of Long-Term Care

Conference Insider

Zarxio Switching Fails to Meet Budget Impact Model Expectations

05/10/2017

According to research presented at the AMCP 2017 Annual Meeting, Zarxio (filgrastim-sndz; Sandoz) cost savings, predicted using a budget impact model, failed to meet the expectations of researchers due to the drug’s higher price.

According to research presented...

05/10/2017

First Report Managed Care

News

Welcome to the AES 2017 Annual Meeting

11/29/2017

The 71st American Epilepsy Society (AES) Annual Meeting is taking place in Washington, DC, from December 1st through December 5th at the Walter E Washington Convention Center.

Low-grade Upper Tract Urothelial Cancer Videos

What's Trending?

Stay Informed—Sign up today!

Specialties

Events

Year Round Education

HMP Global Products